Lead late-stage

As with safety, environmental considerations are usually left to a late stage in the design. However, like safety, early decisions often can lead to difficult environmental problems which later require complex solutions. Again, it is better to consider effluent problems as the design progresses in order to avoid complex waste treatment systems. 

Poor pharmacokinetics and toxicity are important causes of costly late-stage failures in drug development. It is generally recognized that, in addition to optimized potency and specificity, chemical libraries should also possess favorable ADME/Tox and druglike properties [77-80]. Assessment of druglike character is an attempt to decipher molecular features that are likely to lead to a successful in vivo and, ultimately, clinical candidate [81-83]. Many of these properties can be predicted before molecules are synthesized, purchased, or even tested in order to improve overall lead and library quality. 

Tables 4.32 and 4.33 summarize the metrics for the synthesis plans for both products. The Fukuyama plans to both targets are very similar differing only in the very late stages of each plan. The Kuehne plan to vinblastine is considerably shorter than the Fukuyama one since it uses (—) -vindoline as an available starting material in stage 11. This explains why its overall kernel RME is 17 times larger than that of the Fukuyama plan. For a more fair comparison, if the upper two branches leading to (—)-vindoline are omitted from the Fukuyama plan, the number of stages remain the same at 27 but the number of reactions and inputs decreases to 29 and 47, respectively. These changes result in an increase in overall kernel RME from 0.3% to 0.5% but it is still an order of magnitude less than that determined for the Kuehne...

Intratumoural injection is believed to facilitate vector uptake and expression of p53 in the adjacent tumour cell, leading to cell cycle arrest and apoptosis. Company data showed complete regression of tumours in 64 per cent of patients treated with Gendicine in combination with radiation therapy, with few associated side effects. By 2006 the product was believed to have been administered to some 50 000 patients in China, and is in late-stage clinical trials for various other cancers. 

The number of candidate drugs has increased drastically since the introduction of combinatorial chemistry.13 One drawback is that the compounds generated often do not have favorable biopharma-ceutical and pharmacokinetic properties.1314 For example, drug candidates may be poorly soluble in water, leading to low drug concentrations in GI fluids.1314 Forty percent of late stage failures are linked to poor pharmacokinetic properties.15... 

In several studies on the antiviral effects of NO on HIV-1 infection, the proviral or antiviral effects of NO seem to be strictly related to the active production of NO during HIV-1 infection. The universal speculative interpretation of the dichotomous effect of NO is that overproduction of this substance, especially in the primary infection and in late stages of the disease, leads to active viral replication with consequent harmful effects on the course of the disease. Conversely, low production of NO may cause a reduction in or inhibition of HIV-1 replication, especially during the symptomless stage of the disease, or during treatment with highly active combined antiretroviral drugs. 

Drug development is a long and cost-intensive business. Only after years of lead identification, chemical optimization, in vitro and animal testing can the first clinical trials be conducted. Unfortunately, many projects still fail in this late stage of development after a considerable amount of money has been spent. According to estimates, preapproval costs for a new drug exceed US 800 million [1]. 

An early identification of the best leads is critical, and systematic biological profiling, as with Cerep BioPrint , enables this progress to a great extent. Experience with using this approach in a major pharmaceutical company (Pfizer) has confirmed this. One component of the issue can be stated that it is better to identify the best (not just potency) lead series than to try and find the best candidate from a possibly suboptimal series, which can happen at late stages of lead optimization, where it is very difficult to make major changes to the lead series chemistry. 

Pharmacokinetics and toxicity have been identified as important causes of costly late-stage failures in drug development. Hence, physicochemical as well as ADMET properties need to be fine-tuned even in the lead optimization phase. Recently developed in silica approaches will further increase model predictivity in this area to improve compound design and to focus on the most promising compounds only. A recent overview on ADME in silica models is given in Ref [128]. 

Dementia due to AD steadily worsens, typically over the course of about 10 years, but survival in some patients may be as short as 3 4 years. In late stages AD leads to what is sometimes called a vegetative state, Le. the patient is bedfast and totally dependent on others for all basic living activities. Patients with AD typically die from bronchitis or pneumonia. Risk factors of AD are age, female gender and presence of the apolipoprotein c4 (APO e4) allele. Higher levels of education, moderate levels of daily wine consumption and higher levels of fish in the diet have been associated with a lower risk for AD (Cummings and Cole, 2002). 

Cholinesterase inhibitors are the only class of drugs currently approved by most Health Authorities and recommended by professional associations (e.g. Doody et al.. 2001) for the symptomatic treatment of AD. However, ChE-Is intervene at a late stage of the pathophysiological cascade leading to AD (Fig. 7.2) furthermore, their efficacy is limited and they may cause a number of side effects, most frequently nausea, vomiting, diarrhea, anorexia and dizziness. For these reasons, major efforts are being made to alter the biological processes... 

QSAR retain, however, a certain significance in late stages of lead optimization where they can serve to... 

---